The review emphasises on the strain's robust safety profile and the wealth of scientific data supporting its use for children's optimal development.
“Bifidobacteria are naturally prevalent in microbiota in early life. A healthy balance in the gut microbiota is important in maintaining and supporting newborns’ and infants’ gut health."
"This review summarises the preclinical and clinical evidence available on B. lactis Lafti B94 and describes its role in paediatric populations in various indications."
"B. lactis Lafti B94 is a Generally Recognised as Safe (GRAS) notified for use in non-exempt infant formula from birth, reaffirming its safe use in paediatric population,” summarises corresponding author Sylvie Binda, Vice President of Research and Development at Lallemand Health Solutions.
Key study findings
The review discusses potential mechanisms of action and presents results from nine clinical studies on paediatric populations that highlight the strain's efficacy in safely supporting infant gut health, promoting gut comfort and improving gut transit in times of occasional diarrhoea and constipation.
Moreover, studies on H. pylori and antibiotic-associated diarrhoea demonstrate the potential for B. lactis Lafti B94 to help as an adjuvant and reduce side-effects.
Based on this solid scientific background, B. lactis Lafti B94 has received the following Canadian health claims: from birth, B. lactis Lafti B94 supports intestinal and gastrointestinal health, could promote a favourable gut flora and participates in a healthy microflora balance.
Starting from the age of 4, it helps relieve abdominal discomfort, such as bloating and constipation, and helps children and adolescents with bloating and constipation in irritable bowel syndrome.
In the US, these scientific findings allow the following structure/function claim: helps with occasional bloating and constipation and supports overall gastrointestinal discomfort.
